Truffle Capital SAS

Filings by Truffle Capital SAS span 3 companies, the busiest being Abivax, Affluent Medical and Carbios. In total, 23 filings cover trades dated from 4 November 2021 to 26 June 2026.

On the open market, the record shows 7 purchases worth €12.2M and 10 sales worth €17.2M. The net balance comes to €5.0M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 2 purchases and no sales.

A typical purchase (the median) is worth €1.6M. Of 7 purchases, 1 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 1 July 2026 came the latest disclosure, an open-market purchase for €2.6M in Affluent Medical. Between a trade and the moment it shows up on AMF, the median delay is 5 days. The legal deadline for notifying a trade is three business days (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from AMF disclosures alone and does not predict where the share price will go.